Canertinib Dihydrochloride ≥98%|CAS:289499-45-2|25 mg|100 mg|250 mg

CI1033|Canertinib is an irreversible inhibitor of EGFR (HER2/ErbB). This compound is currently in clinical trials as an anticancer chemotherapeutic, displaying activity against a variety of cancers. In a cellular model of melanoma, canertinib exhibits cytostatic activity, stopping cell growth in the G1 phase, but not inducing apoptosis except at very high concentrations. In a related animal model, canertinib inhibits tumor growth. Separately, canertinib inhibits Akt and ERK1/2 in cells lacking ErbB receptors and induced caspase-mediated apoptosis.|C24H23ClFN5O3 2HCl |558.86||Ambient|